BioWorld

Feb. 18, 2003

Neose Secures $17M Privately To Advance Internal Programs

Neose Technologies Inc. is raising $17 million through a private placement of common stock. The Horsham, Pa.-based company said late Thursday it entered into a definitive agreement to sell about 2.9 million common shares for $6 apiece. (BioWorld Today) Read More

GSK's Decision To Limit Sales Rankles Some Representatives

By Walling Off Cyanide, Scientists Seek Pollution-Free Hydrogen Fuel For Industry, Medical Applications

Vertex, GSK Present Preliminary Results From Two Pivotal Trials

Holiday Notice

BioWorld's offices were closed Monday in observance of the Presidents Day holiday in the U.S. No issue was published that day. Read More

Dolly, A Symbol Of Biotech, Dies At 6 From Lung Disease

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...